tbuckley/cabot-search huggingface dataset:
HYDROSTATIC EYE DOUCHE
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Normal Growth and Development during Adolescence
Authors: Harold C. Stuart
Journal: New England Journal of Medicine (1946)

Skeletal or Osseous DevelopmentThe characteristic picture of the development of the skeleton as seen in roentgenograms of the hand and other areas has been studied in great numbers of children at each age, and standards representing average occurrences have been published. The Atlas of the Hand prepared by Todd26 is the most extensive of these and serves as a practical standard for comparing subjects. Flory27 has prepared an additional set of standards, and a number of other methods have been suggested. Space does not permit a review of the changes taking place year by year throughout adolescence, but the . . .
Commentaire de travail de G. Fernández-Esparrach et al., pp. 292
Journal: Endoscopy (2010)

See also: Endoscopic ultrasound-guided fine-needle aspiration and trucut biopsy in the diagnosis of gastric stromal tumors: a randomized crossover studyEndoscopy 2010; 42(04): 292-299DOI: 10.1055/s-0029-1244074
Re: Siobhan P. Lynch, Yu Shen, Ashish Kamat, et al. Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.020
Authors: Nabil Ismaili
Journal: European Urology (2012)
Abstract MP69: Hypertension, Overweight and Obesity Among US Immigrants: An Analysis of the 2010-2014 National Health Interview Survey
Authors: Yvonne Y Commodore-Mensah, Ruth-Alma Turkson-Ocran, Jonathan Aboagye, Laura Samuel, Carolyn Reilly
Journal: Circulation (2016)

Introduction: Ethnic minority populations in the United States (US) are disproportionately affected by cardiometabolic risk factors including hypertension, overweight/obesity and diabetes. Currently, 13% of the US population are immigrants (41 million), and this number is growing and changing demographically. Hypothesis: We hypothesized that considerable variability will exist in the prevalence of overweight/obesity, diabetes and hypertension among immigrants. Methods: We used the National Health Interview Survey (NHIS) to compare hypertension, overweight and diabetes prevalence in adult US immigrants and pooled years 2010-2014.We calculated age and gender-adjusted prevalence of overweight/obesity, diabetes and hypertension by region of birth using multivariable logistic regression. Results: We included 54,984 participants from Europe(7%),South America(6%), Mexico/Central America/Caribbean(55%), Russia(1%), Africa(4%), Middle East(2%),Indian subcontinent(6%), Central Asia (7%) and Southeast Asia(11%). In age and gender-adjusted estimates, overweight/obesity and diabetes were least prevalent in Central Asian immigrants (32% and 6%, respectively) and most prevalent in Mexico/Central America/Caribbean immigrants (71% and 10%, respectively). The age-and gender adjusted prevalence of hypertension ranged from 17% (South America) to 25% (Russia). Table 1 provides the adjusted multivariable adjusted odds Ratios (OR) of overweight/obesity, diabetes and hypertension. Conclusions: We observed substantial heterogeneity in the prevalence of cardiometabolic risk factors among a nationally representative sample of US immigrants. Immigrants from Mexico/Central America/Caribbean, Africa and Asia had the highest odds for diabetes although Asian immigrants had the lowest odds of overweight/obesity. Our findings support the disaggregation of data on US immigrants to inform culturally-tailored public health strategies to prevent cardiometabolic disease.
Utility of differential leukocyte counts in cancer management
Authors: F. P. Li
Journal: JAMA (1984)

In 1,811 adult patients receiving diverse treatments for cancers other than leukemia, the absolute neutrophil count closely paralleled the total leukocyte (WBC) count. All of the 1,260 patients with WBC counts higher than 5,000/cu mm had more than 1,500 neutrophils per cubic millimeter. Routine differential leukocyte counts are rarely useful in managing the cancer therapy for patients with a WBC count greater than 5,000/cu mm, and only add to the cost of their care. (<i>JAMA</i>1984;252:1312-1314)
Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies.
Authors: Stefan Gluck, Joyce O'Shaughnessy, Kristi McIntyre, Lee Steven Schwartzberg, Sharon Wilks, Shannon Puhalla, Erhan Berrak, James Song, David Cox, Linda T. Vahdat
Journal: Journal of Clinical Oncology (2014)

629^ Background: Eribulin mesylate, a novel nontaxane microtubule dynamics inhibitor, has demonstrated an overall survival benefit relative to other commonly used agents in pts with at least 2 prior MBC therapies. Primary data presented from 2 phase 2 trials, Study 206 (eribulin in HER2- pts) and Study 208 (combination eribulin + trastuzumab [TRAS] in HER2+ pts), showed clinical activity and acceptable tolerability profiles as first-line therapy (tx). Here we present prespecified efficacy data for both trials based on prior anthracycline (A) and taxane (T) use. Methods: In both studies, pts received eribulin mesylate 1.4 mg/m2IV on Days 1 and 8 of each 21-day cycle. Pts in Study 208 (HER2+ pts) also received initial TRAS (8 mg/kg IV/Day 1), followed by 6 mg/kg/Day 1 of each subsequent cycle. Response, progression-free survival (PFS), and tolerability were assessed. Results: In Study 206 (N=56), 48% and 46% received prior A and T, and in Study 208 (N=52), 21% and 44% received prior A and T, respectively. Objective response rates (ORRs), the primary endpoint, were similar in pts, regardless of prior A or T tx, except in pts w/o prior T in Study 208 whose ORR trended higher (table). In both studies, clinical benefit rate (CBR), PFS, and duration of response (DOR) were either similar or trended higher in pts w/o prior A or T. PFS was higher in HER2+ pts receiving eribulin + TRAS who had not received prior A or T compared with those who had. Grade (G) 3-5 AE rates were similar or lower in pts who had not received prior A or T. Conclusions: As first-line therapy, eribulin in HER2- pts and eribulin + TRAS in HER2+ pts were effective and well tolerated, regardless of prior A or T tx. However, in HER2+ pts receiving eribulin + TRAS, the lack of prior A or T tx may be a predictor of longer median PFS. Clinical trial information: NCT01268150 and NCT01269346. Prior A/T use Study 206 (N=56) (eribulin only) Study 208 (N=52) (eribulin/TRAS) A w/o A T w/o T A w/o A T w/o T n 27 29 26 30 11 41 23 29 ORR, n (%) 7 (26) 9 (31) 7 (27) 9 (30) 7 (64) 30 (73) 13 (57) 24 (83) CBR, n (%) 13 (48) 16 (55) 12 (46) 17 (57) 9 (82) 41 (100) 19 (83) 25 (86) PFS, m (median) 5.8 6.9 5.8 7.6 6.7 11.6 6.8 13.1 DOR, m (median) 5.7 7.4 4.7 9.7 11.1 11.8 7.5 11.8
Humidifier fever
Journal: Thorax (1977)

Abstract MRC Symposium (1977).Thorax, 32, 653-663. Humidifier fever. In enclosed environments, it may be necessary to regulate temperature, ventilation, and humidity to maintain comfortable working conditions. Several systems can be used although in terms of installation and running costs a simple radiator system is far more economical than air conditioning with complete temperature and humidity control. Humidity control requires the introduction of water into a moving current of air, and in such a system baffle plates are often used to eliminate large droplets; also any unused water is usually recirculated. Organic dust drawn into the system and settling on the baffle plates and in the mixing chamber may be utilised by micro-organisms introduced from the atmosphere and from the water supply, and a biomass builds up. Microbial material is then voided into the working atmosphere by the ventilation system. Under appropriate exposure conditions susceptible individuals may succumb to an episode of humidifier fever, an influenza-like illness with pyrexia and malaise as the main symptoms, but cough, chest tightness, dyspnoea and weight loss may also be seen. The episodes usually occur after absence from work for a few days and have been termed `Monday sickness'. Individuals are often able to return to work the next day and appear refractory to further exposure. The disease is of the winter months probably due to the larger amount (up to 90%) of fresh air drawn into the humidifier during the summer. In the blood of exposed subjects precipitins are usually present to extracts of baffle plate material and recirculating water although they are not necessarily indicative of disease. Skin tests may be positive and inhalation challenge has reproduced the disease in susceptible individuals. Many organisms may be isolated from baffle plates and recirculating water but only amoeba extracts have produced consistently positive reactions with sera from affected individuals. Remedial actions such as changing from water to steam humidification or running recirculation water to waste have proved effective in some factories. Other measures may be considered, for example, adding microbicidal agents or prefiltering intake air. The pyrexial episode may be due to immune complex-complement or alternative pathway-complement activation, inducing the release of leucocyte pyrogen; alternatively, sensitised lymphocytes can release lymphokines capable of inducing leucocyte pyrogen release.
Abstract 1944: Atorvastatin Reduces Intracerebral Hemorrhage after Experimental Stroke
Authors: Hazem F Elewa, Anna Kozak, David Rychly, Adviye Ergul, Reginald Frye, Azza El-Remessy, Susan C Fagan
Journal: Circulation (2007)

Ischemic stroke is a leading cause of death and disability in the United States and diabetes mellitus is the fastest growing risk factor for stroke. In addition, hyperglycemia, which is usually associated with diabetes, tends to worsen ischemia/reperfusion injury and to induce more oxidative stress damage. Preliminary data from our laboratory showed that diabetic animals (Goto-Kakizaki rats (GKs) are more susceptible to vascular damage leading to intracerebral hemorrhage. Many studies have indicated that statins possess neuroprotective properties even when administered after the onset of ischemia. However, the acute vascular effects of statins after ischemic stroke have not been studied to date. Objective: to evaluate the efficacy and magnitude of vascular protection of acute statin therapy in both GKs and their normoglycemic controls after experimental ischemic stroke. Methods: Male Wistar (W) and GK rats (270–305 g) underwent 3 hours of middle cerebral artery occlusion (MCAO) followed by reperfusion for 21 hours. Animals were randomized to receive either atorvastatin (15mg/Kg) or methyl cellulose (0.5%), administered by oral gavage, the first dose 5 minutes after reperfusion and the second dose after 12 hours. Brain tissue was analyzed for infarct volume and hemoglobin content. In another set of Wistar rats (n=3), atorvastatin (15mg/Kg) was administered by oral gavage to compare its pharmacokinetic profile with that of humans Results: Atorvastatin-treated groups had significantly lower hemoglobin (p=0.0156) and infarct volume (p=0.0132) compared to their controls. Atorvastatin peak concentration (27–77 ng/ml) in rats’ plasma was found to be similar to that seen after 80mg/day of atorvastatin in humans. Conclusion: Atorvastatin can be a novel vascular protective agent after acute ischemic stroke especially in a high risk population like diabetics. The mechanisms through which these effects are mediated are currently being investigated.
Changing character of cervical cancer in young women.
Authors: P. M. Elliott, M. H. Tattersall, M. Coppleson, P. Russell, F. Wong, A. S. Coates, H. J. Solomon, P. M. Bannatyne, K. H. Atkinson, J. C. Murray
Journal: BMJ (1989)

To examine the hypothesis that the pattern of cervical cancer is changing data on women presenting with the disease over 34 years were studied retrospectively. During 1953-86, 2628 women with cervical cancer were referred to a large tertiary referral hospital in Sydney; 418 were aged 35 or less. During the period of review the proportion of young women with the disease increased from under 9% in the 1950s and 1960s to about 25% in the 1970s and 1980s; a similar but less pronounced trend was apparent for the whole of New South Wales in the 1970s and 1980s. The prevalence of less common morphological types of cervical cancer increased throughout the period, particularly in the young. Pelvic lymph node metastases were identified in younger patients with stage Ib and IIa tumours more commonly in the later years of the study, suggesting that the disease was becoming more severe. Overall rates of recurrence improved over time, but an apparent increase in early recurrences was observed in young patients with Ib and IIa tumours and without nodal disease. The results suggest that the clinical and pathological behaviour of cervical cancer changed over the period of review.
Gunshot Injuries. A New Edition of Sir T. Longmore's Work.— Gunshot Injuries; their History, Characteristic Features, Complications and General Treatment; with statistics concerning them as they have been met with in warfare.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).
Authors: Ruben A. Mesa, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Andrew Perkins, Jiri Mayer, Peter Ganly, Eric Jourdan, Harry C. Schouten, Patrizia Tosi, Charles Michael Farber, Pierre Zachee, Christof Scheid, James P. Dean, Paul Cernohous, Jyoti Nangalia, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Adam Mead, Claire N. Harrison
Journal: Journal of Clinical Oncology (2015)

LBA7006 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Saturday, May 30, 2015, and in the Annual Meeting Proceedings online supplement to the June 20, 2015, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.
Effects of Season of Birth on Autism Spectrum Disorders: Fact or Fiction?
Authors: Alexander Kolevzon, Mark Weiser, Raz Gross, Gad Lubin, Haim Y Knobler, James Schmeidler, Jeremy M Silverman, Abraham Reichenberg
Journal: American Journal of Psychiatry (2006)

This study attempted to examine the relationship between month and season of birth and risk for autism spectrum disorders.The cohort included all Jewish individuals born in Israel over 5 consecutive years (N=311,169) and assessed by the Israeli Draft Board as part of the mandatory assessment of eligibility for military service conducted at age 17. The outcome of autism spectrum disorders was ascertained from the Draft Board Medical Registry, which contains information about medical and psychiatric disorders for this population of adolescents.There was no association between month or season of birth and the prevalence of autistic spectrum disorders.The findings from this historical, population-based cohort study do not support an association between season of birth and autistic spectrum disorders.
Mine Eyes Have Seen: A Woman Doctor's Saga
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HOSPITAL PRACTICE REQUIREMENT FOR ARMY MEDICAL SERVICE.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antibodies against human herpesvirus 8 in subjects with non-venereal dermatological conditions
Authors: C. Masini, D.D. Abeni, M.S. Cattaruzza, M. Capuano, C. Pedicelli, F. Cerimele, P. Pasquini, D. Cerimele, G. Fadda, P. Cattani
Journal: British Journal of Dermatology (2000)
Correction
Journal: BMJ (1968)

ILJOURNALment should be limited to women who are not yet sensitized, have no living child, and are shown to have received enough foetal cells to make sensitization likely.The immunoglobulin must be given within 36 hours of delivery to be effective, so it is recommended that women at risk should be admitted to hospital for confinement.Doctors are asked to encourage patients known to be sensitized to the D antigen to become donors.
American Journal of Pathology, New York
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surgery for Acquired Valvular Heart Disease
Authors: John W. Kirklin, Albert D. Pacifico
Journal: New England Journal of Medicine (1973)

Mitral Valvular DiseasePatients operated upon for mitral-valve disease may undergo valvular replacement or valvular repair. Valve function is more variable after repair than after replacement, adding another complexity of analysis of early and late results of the operations.Survival and Complication Rates for Devices Used for Mitral Replacement and for the Repaired Mitral Valve Hospital mortality rates. Special note of the hospital mortality rate is required, since it seems principally related to the type of abnormality at the mitral valve. A group of 200 consecutive patients undergoing isolated mitral valvular replacement in our unit was recently reviewed by . . .